Last reviewed · How we verify
Pembrolizumab, Etoposide, Cisplatin or Carboplatin
Pembrolizumab, Etoposide, Cisplatin or Carboplatin is a Small molecule drug developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. It is currently in Phase 2 development.
At a glance
| Generic name | Pembrolizumab, Etoposide, Cisplatin or Carboplatin |
|---|---|
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
- Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer (PHASE1)
- Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate (PHASE1)
- Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) (PHASE1)
- Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) (PHASE3)
- Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) (PHASE3)
- Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) (PHASE2)
- Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pembrolizumab, Etoposide, Cisplatin or Carboplatin CI brief — competitive landscape report
- Pembrolizumab, Etoposide, Cisplatin or Carboplatin updates RSS · CI watch RSS
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano portfolio CI
Frequently asked questions about Pembrolizumab, Etoposide, Cisplatin or Carboplatin
What is Pembrolizumab, Etoposide, Cisplatin or Carboplatin?
Pembrolizumab, Etoposide, Cisplatin or Carboplatin is a Small molecule drug developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
Who makes Pembrolizumab, Etoposide, Cisplatin or Carboplatin?
Pembrolizumab, Etoposide, Cisplatin or Carboplatin is developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (see full Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline at /company/fondazione-irccs-istituto-nazionale-dei-tumori-milano).
What development phase is Pembrolizumab, Etoposide, Cisplatin or Carboplatin in?
Pembrolizumab, Etoposide, Cisplatin or Carboplatin is in Phase 2.